Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paola Castrignanò

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Review of Clinical Immunology|June 17, 2022
Comparing treatment options for large vessel vasculitisFederica Macaluso, Chiara Marvisi, Paola Castrignanò, et al.
Clinical and Experimental Rheumatology|January 9, 2023
Reply to Comment on: Vasculitis, fibromuscular dysplasia or hereditary aneurysms? by Marvisi et alChiara Marvisi, Paola Castrignanò, Giulia Besutti, et al.
Seminars in Arthritis and Rheumatism|December 24, 2023
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort studyFrancesco Muratore, Chiara Marvisi, Paola Castrignanò, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 6, 2021
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With VasculitisFrancesco Muratore, Chiara Marvisi, Paola Castrignanò, et al.
Journal of Personalized Medicine|July 2, 2021
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast StudyAngela Toss, Amelia Spinella, Chrystel Isca, et al.
Biologics : Targets & Therapy|November 5, 2025
Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0)Marisol Bracalenti, Margherita Zen, Benedetta Bianchi, et al.
Lupus Science & Medicine|May 4, 2026
Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohortGreta Hulej, Federico Arru, Benedetta Bianchi, et al.
Immunotherapy|October 18, 2018
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa studyMelissa Bersanelli, Diana Giannarelli, Paola Castrignanò, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Review of Clinical Immunology|June 17, 2022
Comparing treatment options for large vessel vasculitisFederica Macaluso, Chiara Marvisi, Paola Castrignanò, et al.
Clinical and Experimental Rheumatology|January 9, 2023
Reply to Comment on: Vasculitis, fibromuscular dysplasia or hereditary aneurysms? by Marvisi et alChiara Marvisi, Paola Castrignanò, Giulia Besutti, et al.
Seminars in Arthritis and Rheumatism|December 24, 2023
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort studyFrancesco Muratore, Chiara Marvisi, Paola Castrignanò, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 6, 2021
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With VasculitisFrancesco Muratore, Chiara Marvisi, Paola Castrignanò, et al.
Journal of Personalized Medicine|July 2, 2021
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast StudyAngela Toss, Amelia Spinella, Chrystel Isca, et al.
Biologics : Targets & Therapy|November 5, 2025
Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0)Marisol Bracalenti, Margherita Zen, Benedetta Bianchi, et al.
Lupus Science & Medicine|May 4, 2026
Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohortGreta Hulej, Federico Arru, Benedetta Bianchi, et al.
Immunotherapy|October 18, 2018
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa studyMelissa Bersanelli, Diana Giannarelli, Paola Castrignanò, et al.
Pageof 1